EPCORITAMAB
Information current as at: 1 May 2025
Submission Details
- Brand name:
-
- Epkinly®
- Pharmaceutical company:
- ABBVIE PTY LTD
- Condition/indication:
(therapeutic use) -
- Relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL)
- PBAC Submission type:
- New PBS listing (Category 1)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – November 2024
- Related medicines:
- --
Progress Details
-
Submission received for: - November 2024 PBAC meeting
-
Opportunity for consumer comment: - Open 31/07/2024 and close 25/09/2024 (see PBS Website)
-
PBAC meeting: - Held on 06/11/2024
-
Lodgement of required documentation: - 15/01/2025
-
Acceptance of complete documentation:
- Accepted
-
Agreement to listing arrangements: - Commenced on 10/02/2025
-
Status:
- Finalised
-
Government processes: - Commenced on 17/02/2025
-
Medicine listed on the PBS: - 01/05/2025 (see PBS schedule)
Case ID: a931
Page last updated: 30 April 2025